Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07445958 · ClinicalTrials.gov registry record · NA

In-Clinic Assessment of Vaginal Mucosal Safety Following Repetitive Use of the Livi Device

A NA study, sponsored by Atlantic Health System.

Completed
Registry status
NA
Development phase
60
Enrollment target

NCT07445958: Completed NA study, sponsored by Atlantic Health System.

NCT07445958 is a NA study that has completed, run by Atlantic Health System. The registered enrollment target is 60 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07445958, a NA study, has completed, sponsored by Atlantic Health System.

COMPLETED
Registry status
NA
Development phase
60 participants
Enrollment target

Study Summary

The goal of this clinical trial is to learn if the Livi postcoital tampon device is safe for repetitive use in sexually active women aged 18 years and older. The main question it aims to answer is: Does using the Livi device three times in a row cause any visible vaginal mucosal trauma? How much pain or discomfort do participants experience during insertion and removal? Researchers will not compare the Livi device to another product because this is a single-arm safety study. Participants will: * Insert and remove the Livi device three times consecutively during one clinic visit * Undergo a baseline speculum exam and digital colposcopy exams after each device removal to check vaginal tissue * Complete a 24-hour follow-up via e-diary or phone call to report pain, spotting, or other symptoms * Report any unsolicited symptoms for 7 days after use

Primary Outcome

Incidence of Grade ≥2 vaginal mucosal trauma assessed immediately after device removal via digital colposcopic examination. Mucosal trauma defined as: Grade 2 (Moderate): Abrasion \>5 mm or multiple foci totaling \>10 mm; pinpoint bleeding stopping spontaneously. Grade 3 (Severe): Laceration or bleeding requiring medical intervention.

Interventions

  • DEVICE Livi Postcoital Tampon Device

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2026-01-28
Est. Completion 2026-02-09
Phase NA
Atlantic Health System

43 total trials

What the finished NCT07445958 record still lists

NCT07445958 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 1 intervention - of which Livi Postcoital Tampon Device is the first listed.

NCT07445958 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07445958 about?

NCT07445958 is a clinical study titled "In-Clinic Assessment of Vaginal Mucosal Safety Following Repetitive Use of the Livi Device". The goal of this clinical trial is to learn if the Livi postcoital tampon device is safe for repetitive use in sexually active women aged 18 years and older. The main question it aims to answer is: Does using the Livi device three times in a row cause any visible vaginal mucosal trauma? How much pa...

What is the current status of trial NCT07445958?

This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2026-01-28. Estimated completion is 2026-02-09.

What interventions are being tested in trial NCT07445958?

The interventions under investigation include: Livi Postcoital Tampon Device (DEVICE).

Who is sponsoring clinical trial NCT07445958?

This trial is sponsored by Atlantic Health System, which has 43 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07445958's enrollment target sits among peer trials

60 1164th of 2000 higher than 745 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07445958, the US trial registry maintained by the National Library of Medicine. NCT07445958 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.